The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receive efgartigimod PH20 SC and the other half will receive placebo. In part B, all participants will receive efgartigimod PH20 SC. The participants will be in the study for about up to 2 years and 12 weeks.
Protocol Amendment History
13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-08-14; most recent amendment 2026-07-01.
Status change: Recruiting → Active, Not Recruiting2025-12-10
Status change: Not Yet Recruiting → Recruiting2024-10-08